The Canadian government has granted permission to a startup to ship psychedelic substances to Australia for therapeutic applications. Optimi Health Corp. has been assigned with the responsibility of exporting pills that contain psilocybin, a hallucinogenic compound from magic mushrooms, and MDMA, as authorized by the health department.
The increasing demand goes beyond the local magic mushrooms Ontario. Other countries are taking inspiration from Canada and starting to investigate and authorize the medicinal use of serotogenic compounds.
Confidently buy psychedelics online in Canada and unlock your innate potential through trustworthy sources.
[toc]Key Takeaways:
- Optimi Health, a Vancouver-based startup, has obtained a drug establishment license to export magic mushroom pills to Australia.
- Australia allows licenced psychiatrists to use magic mushrooms in the treatment of chronic depression.
- The treatment consists of three sessions spread over a period of five to eight weeks, with each session lasting around eight hours.
Rise of Psilocybin Capsules in Canada
Optimi, a Vancouver-based startup, aims to use its certification to broaden the pharmaceutical market for psychedelic drugs and secure an early advantage.
Seven companies have shipped psilocybin, MDMA, or both, but only for clinical trial needs. A representative from Canada’s health department could not confirm if these exports were for regular patient use and chose not to reveal the companies due to safety concerns.
This accomplishment puts Optimi in the company of a few international suppliers, with the current market trending more towards clinical use rather than recreational.
What’s in the Pill?
Though the company hasn’t revealed the particular type of mushroom used in the pill, they work with various strains such as Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, to cultivate, test, and extract its psychedelic mushrooms. This quaint town, with a population of roughly 3,000, is situated a three-hour drive east of Vancouver.
Australia’s Encounter with Psychedelic Mushrooms
There’s an estimation that 1 in 5 Australians between the ages of 16 and 85 may wrestle with mental illness. PTSD (post-traumatic stress disorder) could potentially impact 11% of Australians at some point in their lives, while anxiety disorders are common among 17% of the populace.
A plethora of treatments exist for mental conditions, yet not all are effective for each individual. Those who don’t respond to certain therapies often find it difficult to identify a method that works for them, which can leave them more susceptible.
Decoding the Process
Australia has been a pioneer in employing psilocybin, allowing licensed psychiatrists to leverage this controlled substance in treating PTSD and medication-resistant depression.
In a groundbreaking move in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and mushrooms for therapeutic applications. According to the TGA, these substances are safe when used under medical supervision for patients battling severe mental disorders.
This shift has been a game-changer for many mental health professionals and researchers. The usage of these substances will be stringently monitored; it’s not as simple as just taking a pill and going.
The typical treatment plan encompasses three sessions over a period of five to eight weeks. Each session goes on for approximately eight hours, during which the therapist maintains a constant presence with the patient.
Canada’s Role in Psilocybin Research
Canada has become a leading center for psilocybin research, greatly advancing our understanding of this substance. Health Canada, in collaboration with various institutions, is at the forefront of investigating the therapeutic potential of psilocybin in addressing diverse mental health disorders.
Research institutions are no longer obligated to label these substances as illegal or rely on unregulated dispensaries or mushroom stores. The government now permits certain institutions to grow shrooms for research purposes.
The increased availability of substances once deemed harmful provides researchers the opportunity to deepen their understanding of their potential benefits to many people.
A Recurring Trends
In the 1950s, the potential of psychological healing through certain substances was first acknowledged for addressing mental health disorders and substance abuse, including alcoholism. British psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer were pioneers in this early research at the Saskatchewan Mental Hospital in Weyburn. Under the leadership of then-premier Tommy Douglas, the medical community was given considerable autonomy to explore their medical theories, leading to significant advancements.
Dr. Osmond and Dr. Hoffer initiated investigations with psychedelic substances like LSD, mescaline, and peyote, proposing them as potential alternatives to the harsh treatments of electroshock and lobotomy. Their research took unexpected turns, with the pair endorsing the experimental use of these drugs by medical professionals, including doctors, nurses, and supporting staff.
Research at Canadian Health Institutes
The Institute of Neurosciences, Mental Health and Addiction, part of the Canadian Institutes of Health Research, is funding three clinical trials to investigate the therapeutic efficacy and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Leading Investigator | Project Budget |
| A randomized controlled trial | Psychological distress in terminal cancer patients | University of Toronto | Sarah Hales | $928,643 |
| Investigating mechanisms supporting psilocybin psychotherapy in treating alcohol use disorder | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial comparing single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This research funding will support a more in-depth understanding of the benefits of regulated substances. It has been made viable by the Government of Canada’s Canadian Drugs and Substances Strategy (CDSS).
Further Research in Psychedelics
Psychiatrists in Vancouver have initiated a phase III clinical trial of MDMA, commonly known as ecstasy, for treating post-traumatic stress disorder (PTSD). The treatment protocol includes three eight-hour sessions with MDMA, spaced one month apart, and nine additional sessions lasting 90 minutes each without the drug. This trial is considered historically significant as it marks the first clinical evaluation of an illicit substance for therapeutic purposes.
It has been over four decades since a psychedelic substance emerged.
Deciphering Psilocybin
Psilocybin, a psychedelic compound naturally found in certain mushrooms, transforms into psilocin when ingested. The psilocin activates the serotonin 5-HT2a receptors situated on the cortical pyramidal cells in the brain, which are the key processing areas.
Local authorities are investigating the substance for its potential benefits in treating depression, anxiety, addiction, and end-of-life distress by promoting introspection and spiritual growth.
Why is it Potentially Effective for Depression, PTSD, and Other Conditions?
The active component influences several brain regions, making it potentially beneficial for various mental disorders. Numerous patients in Canada and Australia have experienced this treatment, and the results have shown promise, with minor side effects such as temporary anxiety or elevated blood pressure.
Impact on Neurobiology
- Serotonin Receptor Activation: This compound functions as a partial agonist at serotonin receptors, particularly the 5-HT2A subtype, which is essential for emotional processing and mood regulation.
- Default Mode Network (DMN) Regulation: The substance reduces activity in the DMN, which promotes introspection, decreases rigid thinking patterns, and enhances emotional adaptability.
- Stimulation of Prefrontal and Limbic Regions: The antidepressant effects of the compound stem from its impact on the prefrontal and limbic brain regions, including the amygdala. In depression cases, a person usually shows a reduced response to emotional stimuli. This compound increases the response to positive emotional stimuli in the right amygdala and dampens or normalizes the reaction to negative or neutral emotional stimuli.
Psychological and Emotional Effects:
- Inducing Positive Mood States: Promotes emotions of euphoria, interconnectedness, and emotional openness during and after the experience.
- Enhanced Emotional Processing: The psychedelic experience may help individuals confront and process deeply buried emotions, traumatic memories, or existential concerns in a supportive setting.
- Spiritual and Existential Insights: Research from Johns Hopkins University and Imperial College London suggests that it can lead to enduring beneficial changes, such as better well-being, improved life satisfaction, and spiritual growth.
What Products Are Available at Your Local Magic Mushroom Shops?
Interested in how the substance might affect your mental state? Explore the offerings at magic mushroom stores to find a product that suits your preferences.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Boosts mood, stimulates creative thinking, and enhances productivity and focus |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Fosters improved wellness and enhances overall life satisfaction |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Facilitates clarity, creativity, and concentration. Contains a potent mix of clinical strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Delivers cognitive and energy advantages |
Worldwide Acceptance of Psilocybin
Canada is not the only country advocating the use of magic mushrooms for mental health concerns. Countries like Australia are also embracing these hallucinogens to manage conditions such as depression and PTSD. They obtain high-quality psychedelic capsules from trustworthy sources. With proper supervision, patients can significantly improve their life quality. Funguyz Canada, a magic mushroom supplier, offers a variety of products, from tablets to LSD edibles.
Frequently Asked Questions
How are psilocybin and MDMA similar?
Both psilocybin and MDMA have therapeutic potential by enhancing mental health. Psilocybin interacts with serotonin 2A receptors and is effective in addressing depression and addiction.
Conversely, MDMA cultivates empathy and is beneficial in PTSD therapy. It shows promise in boosting emotional processing and
Despite being classified as a controlled substance, it has demonstrated beneficial therapeutic effects.
Is this treatment option available to all Australians?
No, not all Australians can avail of this treatment option. In Australia, a preliminary assessment is conducted to determine an individual’s suitability for using the substance. Factors such as existing heart conditions, history of psychosis, among others, are taken into account. This treatment is only accessible to patients who have not shown improvement with traditional treatments for conditions such as depression, anxiety, or PTSD.
What are the implications of Canada’s mushroom exports?
Canada is positioning itself to become a leader in the psychedelic market, much like it did with cannabis. This could encourage more companies to produce high-quality products. As a result, Canada could potentially become a powerhouse in the hallucinogen market, boost its economy, and allow other countries to have easier access to these treatments. This move could also discourage other countries from obtaining their hallucinogens from illegal dispensaries or suppliers, thereby ensuring safety.
Articles That Might Interest You:
